# Venlafaxine: Why This Common Antidepressant May Be Riskier Than Most SSRIs This review of published research warns that venlafaxine, a commonly prescribed antidepressant, carries more serious risks than most selective serotonin reuptake inhibitor (SSRI) antidepressants, including a higher chance of fatal overdose and cardiovascular side effects. While venlafaxine works similarly to SSRIs for treating depression, it offers no proven advantage in effectiveness, making it a less attractive treatment option for most patients. The evidence reviewed as of mid-2015 consistently points to dose-dependent blood pressure elevation, heart rhythm problems, and pregnancy complications. For most patients, an SSRI other than citalopram or escitalopram represents a safer choice. # Venlafaxine: Why This Common Antidepressant May Be Riskier Than Most SSRIs ## Table of Contents - Key Points - Understanding Venlafaxine and How It Works - Why This Research Matters to Patients - How the Review Was Conducted - Key Findings: The Evidence in Detail - What This Means for Patients - Study Limitations: What the Evidence Couldn't Prove - Recommendations for Patients and Doctors - Frequently Asked Questions - Source Information ## Key Points - Venlafaxine has a higher risk of fatal overdose and cardiovascular side effects than most SSRIs. - Venlafaxine offers no proven advantage in effectiveness over SSRIs for treating depression. - Venlafaxine can cause dose-dependent blood pressure elevation and QT prolongation, a heart rhythm abnormality. - Taking venlafaxine in the second and third trimesters of pregnancy increases risk of pre-eclampsia and eclampsia. - For most patients, an SSRI other than citalopram or escitalopram is a safer choice than venlafaxine. ## Understanding Venlafaxine and How It Works Venlafaxine (brand name Effexor and others) is an antidepressant that belongs to a class of medications known as **serotonin and norepinephrine reuptake inhibitors (SNRIs)**. It works by blocking the reuptake of two brain chemicals—serotonin and norepinephrine—both of which play important roles in regulating mood, energy, and stress responses. In contrast, **selective serotonin reuptake inhibitors (SSRIs)**, such as fluoxetine (Prozac), sertraline (Zoloft), and paroxetine (Paxil), affect only serotonin. This difference in mechanism is central to why venlafaxine has a distinct safety profile. Because venlafaxine also increases norepinephrine activity, it triggers what the review calls **noradrenergic adverse effects**—side effects related to the body's noradrenaline (norepinephrine) system. The most significant of these involve the cardiovascular system. The review notes that venlafaxine reproduces all the serotonergic side effects seen with SSRIs—such as nausea, sexual dysfunction, and gastrointestinal disturbances—while **additionally** introducing cardiovascular risks that SSRIs generally do not carry. This combination of overlapping and extra risks is the cornerstone of the safety concern. It is also important to note what the review found regarding effectiveness: venlafaxine offers **no demonstrated advantages over SSRIs in terms of efficacy**. Both drug classes produce similar results in treating depression, meaning patients get the same potential benefit with venlafaxine but at a higher cost in terms of side effects and risks. ## Why This Research Matters to Patients Depression affects hundreds of millions of people worldwide, and antidepressants are among the most frequently prescribed medications. When a patient is diagnosed with depression, the choice of antidepressant can shape their daily life for months or years. Side effects influence whether patients stay on their medication, and some side effects—particularly heart-related ones—can be dangerous. This review matters because it synthesizes multiple lines of evidence—clinical trials, overdose databases, pregnancy registries, and large national health records—to give a comprehensive picture of venlafaxine's harms. The conclusion is clear and actionable: for most patients, the risk-benefit balance favors SSRIs over venlafaxine. Understanding these risks is especially important for patients currently taking venlafaxine or those considering it. The findings do not suggest that everyone on venlafaxine is in immediate danger, but they do indicate that doctors and patients should carefully weigh whether continued use is justified. ## How the Review Was Conducted This is a **narrative review article** published in *Prescrire International*, a peer-reviewed journal known for rigorous, independent assessments of medications. The review drew on multiple sources of evidence available as of mid-2015: - **Cohort studies** using a UK primary care database that tracked overdose outcomes in patients taking venlafaxine versus SSRIs - **Meta-analyses** of more than 70 published and unpublished randomized clinical trials, including about 7,000 patients in total - **Epidemiological studies** examining pregnancy outcomes in women exposed to venlafaxine - **Observational studies** of elderly patients and reported suicide attempts involving venlafaxine overdose - **Large national cohort studies** from Britain and Denmark investigating sudden cardiac death By combining clinical trial data with real-world epidemiological evidence, the review aimed to capture both the controlled-experiment view of side effects and the messier reality of how the drug performs in everyday use, including in overdose situations. The review did not perform new statistical analyses of its own. Instead, it carefully aggregated and weighed existing studies to identify consistent patterns and to evaluate the strength and limitations of each source of evidence. ## Key Findings: The Evidence in Detail ### Fatal Overdoses Are More Common With Venlafaxine Several cohort studies using data from a UK database found a disturbing pattern: **venlafaxine overdoses are more frequently fatal than SSRI overdoses**. In practical terms, a patient who takes too much venlafaxine is more likely to die from the overdose than a patient who takes too much of an SSRI. This difference is thought to relate to venlafaxine's effects on the heart and blood vessels, which can be overwhelming in overdose. ### Higher Rates of Treatment Discontinuation Due to Side Effects Meta-analyses pooling results from more than 70 randomized clinical trials—including studies that were never published, which helps reduce publication bias—showed that **treatment discontinuation due to adverse effects is more common with venlafaxine than with SSRI antidepressants**. These trials included about 7,000 patients in total, giving the finding substantial statistical weight. Stopping a medication because of side effects is clinically meaningful. It means patients are suffering through uncomfortable or dangerous effects, and it often leads to switching drugs or abandoning treatment altogether, which can leave depression untreated. ### Dose-Dependent Blood Pressure Elevation Venlafaxine can provoke **dose-dependent blood pressure elevation**. This means that as the dose goes up, so does blood pressure, sometimes to levels that require the medication to be stopped. For patients with existing hypertension or heart disease, this effect is especially concerning. Blood pressure elevation is a direct consequence of venlafaxine's noradrenergic action: norepinephrine constricts blood vessels and increases cardiac output, raising pressure within the arteries. Prolonged elevation can damage the heart, kidneys, eyes, and brain. ### Pregnancy Risks: Pre-Eclampsia and Eclampsia Exposure to venlafaxine during the **second and third trimesters of pregnancy increases the risk of pre-eclampsia and eclampsia**. Pre-eclampsia is a serious condition characterized by high blood pressure and signs of organ damage, usually affecting the kidneys and liver, during pregnancy. Eclampsia is a more severe, life-threatening progression that can cause seizures and coma. These risks are particularly noteworthy because pregnancy itself already places strain on the cardiovascular system, and venlafaxine's blood pressure effects compound that strain. For pregnant women with depression, the choice of antidepressant therefore requires careful consideration of fetal and maternal safety. ### Heart Rhythm Abnormalities: QT Prolongation and Torsades de Pointes A cohort study involving about **50 elderly patients** and analysis of **several hundred reported suicide attempts by venlafaxine overdose** demonstrated a risk of **QT interval prolongation**. The QT interval is a measure of the electrical activity of the heart on an electrocardiogram (ECG); when it becomes abnormally long, the heart's electrical system becomes unstable. QT prolongation can lead to **torsades de pointes**, an unusual and potentially fatal type of ventricular tachycardia (a rapid, abnormal heart rhythm originating in the lower chambers of the heart). Torsades de pointes may degenerate into ventricular fibrillation, which is immediately life-threatening. This finding means that venlafaxine in overdose—and possibly at therapeutic doses in vulnerable individuals such as the elderly—can set the stage for catastrophic heart rhythm disturbances. Patients with pre-existing heart conditions or those taking other medications that prolong the QT interval may face even higher risks. ### Sudden Cardiac Death: A Nuanced Picture Large British and Danish cohort studies found **no increased risk of sudden cardiac death with venlafaxine compared with other antidepressants**. This might sound like reassuring news, and in one sense it is: at a population level, venlafaxine did not stand out as causing more sudden deaths than its alternatives. However, this finding must be interpreted with caution, as discussed below in the limitations section. ## What This Means for Patients The overall picture assembled by this review is consistent with what doctors know about venlafaxine's pharmacology. Because venlafaxine works on both serotonin and norepinephrine, it inherits the serotonergic side effects of SSRIs and adds a layer of noradrenergic cardiovascular risks. None of this would be especially problematic if venlafaxine were dramatically more effective than SSRIs—but it is not. The key takeaway is that **venlafaxine has a higher risk of cardiovascular adverse effects and fatal overdoses than most SSRI antidepressants, with no compensatory benefit in treating depression**. When two treatments offer the same chance of improvement but one carries more serious risks, the safer option is generally preferable. For patients considering antidepressant therapy, this means that SSRIs are a **more reasonable first-line option** in most cases. The exception noted in the review involves two specific SSRIs, citalopram (Celexa) and its close relative escitalopram (Lexapro), which also expose patients to more cardiovascular adverse effects than other SSRIs, including QT prolongation. For those two drugs, the same risk-benefit logic that argues against venlafaxine applies with some force. ## Study Limitations: What the Evidence Couldn't Prove The review is honest about the limits of the available evidence, and patients should be aware of these caveats. Regarding sudden cardiac death, the large British and Danish cohort studies that found no increased risk enrolled relatively few venlafaxine users: only **3.5% and 7% of the patients in those studies** were actually taking venlafaxine. This means the studies had **relatively low statistical power** to detect a true difference if one existed. A study with low statistical power can fail to detect a real effect, producing a "no difference" result that is really an "unable to detect a difference" result. In plain language: the absence of evidence of increased sudden cardiac death is not the same as evidence of absence. The review also notes that its conclusions rest on data available as of mid-2015. Since then, additional research may have emerged that could refine or change these conclusions, although no major paradigm shift is indicated by the included studies. Another caveat is that the elderly cohort study of QT prolongation was small (about 50 patients). While the suicide attempt data added weight, the sample sizes in this area are not large enough to precisely quantify the risk of torsades de pointes in everyday therapeutic use as opposed to overdose. Finally, the review is based on aggregate evidence rather than individual patient data, which limits the ability to explore how risk varies with patient characteristics like age, sex, genetic differences in drug metabolism, or coexisting medical conditions. ## Recommendations for Patients and Doctors Most patients will come to this information in one of two situations: they are prescribed venlafaxine and want to understand it, or they are currently taking it and wondering whether to continue. Here is practical guidance based on the review: ### For Patients Considering a New Antidepressant 1. **Discuss SSRIs first.** For most patients with depression, an SSRI offers a better balance of benefit and risk than venlafaxine. Ask your doctor specifically about fluoxetine, sertraline, paroxetine, or similar agents. 1. **Be cautious with citalopram and escitalopram.** If cardiovascular risks are a personal concern, note that these two SSRIs also carry more cardiovascular adverse effects than other SSRIs. Mention any personal or family history of heart problems to your doctor. 1. **Ask about your heart.** If your doctor recommends venlafaxine for any reason, ask whether an ECG to check your QT interval would be appropriate, especially if you are older or take other medications. 1. **Know your blood pressure baseline.** Venlafaxine can raise blood pressure in a dose-dependent way. If you take it, regular blood pressure monitoring is essential. ### For Patients Currently Taking Venlafaxine 1. **Do not stop abruptly.** Stopping venlafaxine suddenly can cause severe withdrawal symptoms, including dizziness, nausea, headache, and electrical shock-like sensations. Any change should be planned with your doctor. 1. **Have an honest conversation.** Ask your doctor whether the reasons for prescribing venlafaxine are still valid, and whether an SSRI switch is worth considering. The evidence suggests most patients would do equally well on an SSRI with fewer risks. 1. **Monitor for warning signs.** If you experience palpitations, fainting, seizures, severe headache, or significantly elevated home blood pressure readings, seek medical attention promptly. 1. **If pregnant or planning pregnancy, talk to your obstetric provider.** The increased risk of pre-eclampsia and eclampsia during the second and third trimesters warrants careful monitoring of blood pressure and close prenatal follow-up. 1. **Safe storage matters.** Because venlafaxine overdoses are more frequently fatal than SSRI overdoses, secure storage of the medication—and limiting the quantity dispensed—is a reasonable precaution, particularly for patients with suicidal thoughts. ### For Doctors and Prescribers The review is unambiguous in its conclusion: **venlafaxine is best avoided in most circumstances**. Because venlafaxine and SSRIs have similar and limited efficacy, and because venlafaxine carries greater cardiovascular risk and overdose lethality, an SSRI is a more reasonable option for most patients. Prescribing venlafaxine should be reserved for situations where SSRIs have failed, are contraindicated, or where there is some specific reason to expect an advantage—and even then, with careful cardiovascular monitoring. ## Frequently Asked Questions ### Is venlafaxine riskier than other antidepressants? Yes, a review of published research found venlafaxine has a higher risk of fatal overdose and cardiovascular side effects than most SSRIs. It also causes more side-effect-related treatment discontinuation. Venlafaxine offers no proven advantage in effectiveness over SSRIs, so for most patients, an SSRI other than citalopram or escitalopram is a safer choice. ### How does venlafaxine cause heart problems? Venlafaxine can cause dose-dependent blood pressure elevation and heart rhythm abnormalities called QT prolongation, which can lead to a dangerous rhythm called torsades de pointes. These risks come from its effect on norepinephrine. In one study of about 50 elderly patients and several hundred overdose cases, QT prolongation was observed. ### Can venlafaxine overdose be fatal? Yes. Cohort studies using a UK primary care database found venlafaxine overdoses are more frequently fatal than SSRI overdoses. This is likely due to its effects on the heart and blood vessels, which can be overwhelming in overdose. Safe storage and limiting the quantity dispensed are reasonable precautions, especially for patients with suicidal thoughts. ### What are the risks of taking venlafaxine during pregnancy? Exposure to venlafaxine during the second and third trimesters of pregnancy increases the risk of pre-eclampsia and eclampsia, serious conditions involving high blood pressure and organ damage. Eclampsia can cause seizures and coma. If you are pregnant or planning pregnancy, talk to your obstetric provider about careful blood pressure monitoring and prenatal follow-up. ### Should I stop taking venlafaxine if I’m worried about these risks? Do not stop abruptly. Stopping suddenly can cause severe withdrawal symptoms, including dizziness, nausea, headache, and electric shock-like sensations. Have an honest conversation with your doctor about whether continued use is justified and whether switching to an SSRI might be appropriate. The evidence suggests most patients would do equally well on an SSRI with fewer risks. ### If I take venlafaxine, what should I monitor? Monitor your blood pressure regularly because venlafaxine can raise it in a dose-dependent way. Seek medical attention promptly if you experience palpitations, fainting, seizures, severe headache, or significantly elevated home blood pressure readings. If you are older or take other medications, ask your doctor whether an ECG to check your QT interval would be appropriate. ### Is venlafaxine more effective than SSRIs for depression? No. The review found venlafaxine offers no demonstrated advantages over SSRIs in terms of efficacy. Both drug classes produce similar results in treating depression. This means patients get the same potential benefit with venlafaxine but at a higher cost in terms of side effects and risks, making SSRIs a more reasonable first-line option for most patients. ### Should I get a second opinion before starting venlafaxine for depression? Yes, a second opinion can help you weigh the risks. Venlafaxine has a higher risk of fatal overdose and cardiovascular side effects than most SSRIs, with no proven advantage in effectiveness. For most patients, an SSRI other than citalopram or escitalopram is a safer choice. If your doctor recommends venlafaxine, a second opinion can confirm whether it is truly necessary or if a safer alternative exists. Diagnostic Detectives Network provides independent expert second opinions. ## Source Information **Original article title:** Venlafaxine more dangerous than most selective serotonergic antidepressants - PubMed **Publication:** *Prescrire International*, April 2016, volume 25, issue 170, pages 96–99 **PMID:** 27186622 **Authors:** No individual authors listed (review produced by the Prescrire editorial team) **Publication type:** Peer-reviewed review article This patient-friendly article is based on peer-reviewed research published in the National Library of Medicine's PubMed database. It explains and contextualizes the original review for a general audience but does not replace professional medical advice. Always consult a qualified healthcare provider regarding any questions about antidepressant medications, dosing changes, or treatment decisions. --- Publisher: Diagnostic Detectives Network (https://diagnosticdetectives.com) — independent multi-expert medical second opinions, worldwide, private-pay. Author byline: Anton Titov, MD, PhD. Contact: https://diagnosticdetectives.com/pages/contact Canonical page: https://diagnosticdetectives.com/products/venlafaxine-why-this-common-antidepressant-may-be-riskier-than-most-ssris